Global Endometriosis Drug Market is segmented By Age Group (Child, Adult, Senior), By Study Phases (Early Phase, Phase 1, Phase 2, Phase 3, Phase 4), By Study Type (Interventional, Observational), By Drug Class (Gonadotropins Releasing Hormone agonists, Progestin, Non-Steroidal Anti-Inflammatory drugs, Oral contraceptive pills), By Route of Administration (Oral, Nasal Spray, Intrauterine Systems, Parenteral), By Therapy Type (Pain Management, Hormonal Therapy), By Distribution Channel (Pharmacies, E-Commerce, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
Global Endometriosis Drug Market is estimated to reach a market value of USD 1807.78 million by 2018 and the market is estimated to grow at a CAGR of 10.4% in the forecasted period 2024-2031.
Endometriosis is a painful ailment in which tissue analogous to the tissue that usually lines the inside of the uterus (endometrium) grows outside the uterus. Endometriosis most commonly involves ovaries, fallopian tubes, and the tissue lining pelvis. Endometriosis is rarely encountered outside the area of the pelvic organs.
Market Summary
|
Metrics |
Details |
|
Market CAGR |
10.4% |
|
Segments Covered |
By Type, By Therapy Type, By Route of Administration, By End User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Market Dynamics
Increased awareness about the disease, growing trend in the adoption of the oral contraceptive pill, and increased incidents of endometriosis due to improved diagnostics techniques are some of the major factors driving the market's growth.
With the increasing burden of endometriosis, awareness and new product developments drive global market growth.
According to the WHO, Endometriosis affects roughly 10% (190 million) of reproductive age women and girls globally; also, as per the ENDOMETRIOSIS UK, 1 in 10 women of reproductive age in the UK suffer from endometriosis, and the prevalence of endometriosis in women with infertility be as high as to 30–50% making it the second most common gynecological condition in the UK affecting 1.5 million women, a similar number of those affected by diabetes which costs the UK economy £8.2bn a year in treatment, loss of work and healthcare costs. Moreover, the increased efforts to improve the diagnosis and treatment drive the global market. European researchers have created new guidelines for diagnosing and treating endometriosis and have significantly updated five key areas in managing the condition, including diagnosis, treatment, and recurrence, which will help patients and clinicians better understand and manage the condition.
The rising efforts to spread awareness about endometriosis are also contributing to the global market growth; like the Endometriosis Association Austria (EVA) On 12 March 2022 hosted a free, full-day, online congress on endometriosis for the second time, WHO collaborated with civil society and endometriosis patient support groups to join the effort of spreading awareness and support. Researchers have also been working to understand the disease and its symptoms better to improve diagnosis and treatment. For instance, the development of a new diagnostic method like the Endotest saliva test for quickly detecting endometriosis by Ziwig SAS launched on 11 February 2022, which is a non-invasive and easy-to-use test and relies on Next-generation Sequencing of micro-RNA present in saliva and with the artificial intelligence to exercise the large amount of data generated.
Ineffective drug therapies and poor success rates restrain the global endometriosis drug market growth.
However, ineffective drug therapies and poor success rates are the major factors restraining the market’s growth.
COVID-19 Impact Analysis
During the COVID-19 pandemic, the awareness camps were either canceled or postponed or switched to online mode, reducing the population pool as regulations such as social distancing was employed to contain the virus. Furthermore, most research facilities were shut down or working on a reduced force, which prolonged the research project. Moreover, regular gynecologist checkups were difficult, leaving most endometriosis patients undetected, negatively impacting the global market during the pandemic.
Market Segment Analysis
Hormone therapy is expected to have a greater grasp on the endometriosis drug market during the forecast period (2022-2029)
Hormone therapy accounted for the largest share of the global market during 2021 and is expected to dominate throughout the forecast period (2022-2029) owing to the increasing clinical research and new product developments. For instance, as per clinicaltrials.gov, currently, 4 interventional trials are recruiting to study hormonal treatment for endometriosis, such as a study to evaluate the Dienogest versus GnRH-a pre-treatment in women with endometriosis undergoing IVF, sponsored by American University of Beirut Medical Center with an estimated study completion date of February 22, 2023, and a study of Elagolix for fertility enhancement clinical trial (EFFECT) financed by Wake Forest University Health Sciences and estimated to be finished by December 2022. Furthermore, the launch of new products such in May 26, 2021, the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for endometriosis.
Market Geographical Share
North America is expected to command dominating the global endometriosis drug market.
North America dominated the global market in 2021 and is expected to dominate throughout the forecast period (2022-2029) owing to the high prevalence of endometriosis in this region. For instance, according to Johns Hopkins Medicine, endometriosis affects an estimated 2% to 10% of American women aged 25-40. Also, as per Office on Women's Health, more than 11% of American women between 15 and 44 are affected by endometriosis. Furthermore, the presence of many government and non-government organizations spreading awareness about endometriosis in North America contributes to the dominance of this region over the global market. Moreover, the key market players such as Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company and AbbVie, holding a majority of the market share, are US based, ensuring the command of North America over the global endometriosis drug market during the forecast period.
Endometriosis Drug Market Companies and Competitive Landscape
The global endometriosis drug market is competitive because of a large drug pipeline, which will probably dominate the market. Some key players are Eli Lilly and Company, Pfizer Inc., Bayer, AstraZeneca, Novartis AG, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Johnson & Johnson Services, INC., AbbVie and GlaxoSmithKline plc. These players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and performing alliances. For instance, in August 16, 2022, GSK acquired Affinivax, Inc. Also, in December 22, 2021, Novartis acquired Gyroscope Therapeutics.
AstraZeneca plc
Overview:
AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK. AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Product Portfolio:
The product portfolio of AstraZeneca plc for endometriosis drugs has ZOLADEX.
The global endometriosis drug report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
